Latin American Patients With Diabetes Prefer SGLT2 Inhibitors

Findings from a recent study highlight the need for clear discussions between patients and physicians before defining a treatment strategy.

Related Keywords

Mexico City ,Distrito Federal ,Mexico ,La Plata ,Buenos Aires ,Argentina ,United States ,America ,American ,Susana Vanoni ,Carmen Castillo Galindo ,National University ,Latin American Diabetes Association ,Plata Institute Of Cardiology ,School Of Medical Sciences ,Latin American ,Patient Preference ,Esteban Costa Gil ,Castillo Galindo ,Between June ,Medical Sciences ,Medscape Spanish ,Latin America ,Diabetes Mellitus Type 2 ,Iabetes Mellitus Type Ii ,Type 2 Diabetes ,Diabetes Mellitus ,Hypertension ,Sglt2 Inhibitors ,Odium Glucose Transporter 2 Inhibitors ,Odium Glucose Co Transporter 2 Inhibitors ,Sodium Glucose Cotransporter 2 Inhibitors ,Dpp 4 Inhibitors ,Dipeptidyl Peptidase 4 Inhibitors ,Glycemic Index ,Glycemic Load ,Physician Patient Decision Making ,Patient Counseling ,Rovider Patient C ,